Prediabetes remission in people with obesity

Affiliations

¹ Department of Medicine and Department of Population Health, New York University Grossman School of Medicine, Holman Division of Endocrinology, Diabetes and Metabolism, VA New York Harbor Healthcare System, New York, NY 10010, USA. Electronic address: michael.bergman@nyulangone.org.

Comment

Michael Bergman. Lancet Diabetes Endocrinol. 2024 Sep.

. 2024 Sep;12(9):603-605.

doi: 10.1016/S2213-8587(24)00193-1. Epub 2024 Jul 29.

¹ Department of Medicine and Department of Population Health, New York University Grossman School of Medicine, Holman Division of Endocrinology, Diabetes and Metabolism, VA New York Harbor Healthcare System, New York, NY 10010, USA. Electronic address: michael.bergman@nyulangone.org.

No abstract available

Conflict of interest statement

I declare no competing interests.

Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.
McGowan BM, Bruun JM, Capehorn M, Pedersen SD, Pietiläinen KH, Muniraju HAK, Quiroga M, Varbo A, Lau DCW; STEP 10 Study Group. McGowan BM, et al. Lancet Diabetes Endocrinol. 2024 Sep;12(9):631-642. doi: 10.1016/S2213-8587(24)00182-7. Epub 2024 Jul 29. Lancet Diabetes Endocrinol. 2024. PMID: 39089293 Clinical Trial.